International hotel group Meininger manages its successful market entry in Switzerland and opens new hotels in Zürich Greencity (174 rooms, 582 beds) and Genève Centre Charmilles (104 rooms, 362 beds). Vischer advises Meininger on any Swiss
Tags :Vischer
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
Vischer has acted as legal counsel to TargImmune Therapeutics, a private Swiss-based biotechnology firm, on the closing of its 2021 financing round, raising CHF 17.7 million. The Vischer legal team was led by Matthias Staehelin (pictured) with
Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Dermavant Sciences, a clinically focused biopharmaceutical company dedicated to developing and commercializing innovative therapies in the field of immune dermatology, has signed a $160 million revenue interest purchase and sale agreement with three participants for its
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as
Ubitec, a developer of software solutions for digitization, was taken over by Swiss IT services provider Umb Solution. Umb is strengthening its range of services for the digitization of applications and processes by adding ubitec’
Faveeo, a Swiss start-up operating an AI-driven trusted content platform, announced the successful closing of its Series B financing round. The investment was led by a private equity fund and various business angels. No financial
DomoSafety, a company in the digital health segment developing solutions in the field of patient safety, announced the successful closing of its Series B financing round. The investment was led by Hirslanden, a Swiss healthcare
Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led
